{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T02:44:39Z","timestamp":1787453079355,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amryt Pharmaceutical"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>\n                        <jats:sc>Abstract<\/jats:sc>\n                     <\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a comparison of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term LDL-C burden and goals achievement in two independent HoFH patients\u2019 cohorts, one treated with lomitapide in Italy (n\u2009=\u200930) and the other with LA in France (n\u2009=\u200929).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The two cohorts differed significantly for genotype (p\u2009=\u20090.004), baseline lipid profile (p\u2009&lt;\u20090.001), age of treatment initiation (p\u2009&lt;\u20090.001), occurrence of cardiovascular disease (p\u2009=\u20090.003) as well as follow-up duration (p\u2009&lt;\u20090.001). The adjunct of lomitapide to conventional lipid-lowering therapies determined an additional 58.0% reduction of last visit LDL-C levels, compared to 37.1% when LA was added (<jats:italic>p<\/jats:italic><jats:sub>adj<\/jats:sub>\u2009=\u20090.004). \nYearly on-treatment LDL-C\u2009&lt;\u200970\u00a0mg\/dl and\u2009&lt;\u200955\u00a0mg\/dl goals were only achieved in 45.5% and 13.5% of HoFH patients treated with lomitapide. The long-term exposure to LDL-C burden was found to be higher in LA than in Lomitapide cohort (13,236.1\u2009\u00b1\u20095492.1 vs. 11,656.6\u2009\u00b1\u20094730.9\u00a0mg\/dL-year respectively, <jats:italic>p<\/jats:italic><jats:sub>adj<\/jats:sub>\u2009=\u20090.002). A trend towards fewer total cardiovascular events was observed in the Lomitapide than in the LA cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In comparison with LA<jats:bold>,<\/jats:bold> lomitapide appears to provide a better control of LDL-C in HoFH. Further studies are needed to confirm this data and establish whether this translates into a reduction of cardiovascular risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01999-8","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T12:12:03Z","timestamp":1631103123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4667","authenticated-orcid":false,"given":"Laura","family":"D\u2019Erasmo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Baldassare","family":"Cefal\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Saheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina","family":"Giammanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Buonaiuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Iannuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Puja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Montalcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pavanello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Vigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Nota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Sampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sbrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Suppressa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Sabb\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Fimiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Cesaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Palmisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"D\u2019Addato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Pisciotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa","family":"Bittar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kalmykova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"B\u00e9liard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Carri\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"issue":"32","key":"1999_CR1","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146\u201357.","journal-title":"Eur Heart J"},{"issue":"11","key":"1999_CR2","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","volume":"102","author":"DM Kolansky","year":"2008","unstructured":"Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Wiegers SE, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102(11):1438\u201343.","journal-title":"Am J Cardiol"},{"issue":"4","key":"1999_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/hrt.44.4.361","volume":"44","author":"JM Allen","year":"1980","unstructured":"Allen JM, Thompson GR, Myant NB, Steiner R, Oakley CM. Cadiovascular complications of homozygous familial hypercholesterolaemia. Br Heart J. 1980;44(4):361\u20138.","journal-title":"Br Heart J"},{"issue":"4","key":"1999_CR4","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jacl.2016.04.006","volume":"10","author":"R Alonso","year":"2016","unstructured":"Alonso R, D\u00edaz-D\u00edaz JL, Arrieta F, Fuentes-Jim\u00e9nez F, de Andr\u00e9s R, Saenz P, et al. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry. J Clin Lipidol. 2016;10(4):953\u201361.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"1999_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/hrt.80.6.583","volume":"80","author":"L Rallidis","year":"1998","unstructured":"Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart. 1998;80(6):583\u201390.","journal-title":"Heart"},{"key":"1999_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2017.01.015","volume":"257","author":"E Bruckert","year":"2017","unstructured":"Bruckert E, Kalmykova O, Bittar R, Carreau V, B\u00e9liard S, Saheb S, et al. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France. Atherosclerosis. 2017;257:130\u20137.","journal-title":"Atherosclerosis"},{"issue":"14","key":"1999_CR7","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","volume":"39","author":"GR Thompson","year":"2018","unstructured":"Thompson GR, Blom DJ, Marais AD, Seed M, Pilcher GJ, Raal FJ. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018;39(14):1162\u20138.","journal-title":"Eur Heart J"},{"issue":"1","key":"1999_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2006.02.030","volume":"189","author":"J Thompsen","year":"2006","unstructured":"Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis. 2006;189(1):31\u20138.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1999_CR9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jacl.2019.05.002","volume":"13","author":"C Stefanutti","year":"2019","unstructured":"Stefanutti C, Pang J, Di Giacomo S, Wu X, Wang X, Morozzi C, et al. A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: the Sino-Roman Study. J Clin Lipidol. 2019;13(4):608\u201317.","journal-title":"J Clin Lipidol"},{"key":"1999_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2018.06.859","volume":"277","author":"FJ Raal","year":"2018","unstructured":"Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: guidelines and new therapies. Atherosclerosis. 2018;277:483\u201392.","journal-title":"Atherosclerosis"},{"issue":"3","key":"1999_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/MOL.0000000000000677","volume":"31","author":"A Bajaj","year":"2020","unstructured":"Bajaj A, Cuchel M. Homozygous familial hypercholesterolemia: what treatments are on the horizon? Curr Opin Lipidol. 2020;31(3):119\u201324.","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"1999_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/CIRCRESAHA.118.313238","volume":"124","author":"RS Rosenson","year":"2019","unstructured":"Rosenson RS, Hegele RA, Koenig W. Cholesterol-Lowering Agents. Circ Res. 2019;124(3):364\u201385.","journal-title":"Circ Res"},{"key":"1999_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/CE.S174169","volume":"14","author":"R Alonso","year":"2019","unstructured":"Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. Core Evid. 2019;14:19\u201330.","journal-title":"Core Evid"},{"issue":"5","key":"1999_CR14","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","volume":"34","author":"L D\u2019Erasmo","year":"2017","unstructured":"D\u2019Erasmo L, Cefal\u00f9 AB, Noto D, Giammanco A, Averna M, Pintus P, et al. Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy. Adv Ther. 2017;34(5):1200\u201310.","journal-title":"Adv Ther"},{"key":"1999_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2147\/VHRM.S36641","volume":"10","author":"A Vuorio","year":"2014","unstructured":"Vuorio A, Tikkanen MJ, Kovanen PT. Inhibition of hepatic microsomal triglyceride transfer protein\u2014a novel therapeutic option for treatment of homozygous familial hypercholesterolemia. Vasc Health Risk Manag. 2014;10:263\u201370.","journal-title":"Vasc Health Risk Manag"},{"issue":"12","key":"1999_CR16","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/14656566.2017.1340941","volume":"18","author":"AJ Berberich","year":"2017","unstructured":"Berberich AJ, Hegele RA. Lomitapide for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2017;18(12):1261\u20138.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"1999_CR17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jacl.2017.03.016","volume":"11","author":"A Gallo","year":"2017","unstructured":"Gallo A, Giral P, Carri\u00e9 A, Carreau V, B\u00e9liard S, Bittar R, et al. Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11(3):704-711.e2.","journal-title":"J Clin Lipidol"},{"issue":"20","key":"1999_CR18","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","volume":"124","author":"FJ Raal","year":"2011","unstructured":"Raal FJ, Pilcher GJ, Panz VR, van Deventer Hendrick E, Brice BC, Blom DJ, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124(20):2202\u20137.","journal-title":"Circulation"},{"key":"1999_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2019.09.006","volume":"290","author":"A Pottle","year":"2019","unstructured":"Pottle A, Thompson G, Barbir M, Bayly G, Cegla J, Cramb R, et al. Lipoprotein apheresis efficacy, challenges and outcomes: a descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989\u20132017. Atherosclerosis. 2019;290:44\u201351.","journal-title":"Atherosclerosis"},{"key":"1999_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2018.08.007","volume":"277","author":"S Beliard","year":"2018","unstructured":"Beliard S, Gallo A, Duch\u00eane E, Carri\u00e9 A, Bittar R, Chapman MJ, et al. Lipoprotein-apheresis in familial hypercholesterolemia: long-term patient compliance in a French cohort. Atherosclerosis. 2018;277:66\u201371.","journal-title":"Atherosclerosis"},{"issue":"6","key":"1999_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/MOL.0b013e3283402f53","volume":"21","author":"GR Thompson","year":"2010","unstructured":"Thompson GR, Catapano A, Saheb S, Atassi-Dumont M, Barbir M, Eriksson M, et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol. 2010;21(6):492\u20138.","journal-title":"Curr Opin Lipidol"},{"issue":"8836","key":"1999_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/0140-6736(93)92542-2","volume":"341","author":"C Keller","year":"1993","unstructured":"Keller C, Gr\u00fctzmacher P, Bahr F, Schwarzbeck A, Kroon AA, Kiral A. LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors. Lancet Lond Engl. 1993;341(8836):60\u20131.","journal-title":"Lancet Lond Engl"},{"key":"1999_CR23","doi-asserted-by":"crossref","unstructured":"Di Taranto MD, Giacobbe C, Buonaiuto A, Calcaterra I, Palma D, Maione G, et al. A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia. J Clin Med. 2020;9(1).","DOI":"10.3390\/jcm9010219"},{"issue":"4","key":"1999_CR24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","volume":"5","author":"FJ Raal","year":"2017","unstructured":"Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017;5(4):280\u201390.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1999_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jacc.2017.11.028","volume":"71","author":"L D\u2019Erasmo","year":"2018","unstructured":"D\u2019Erasmo L, Minicocci I, Nicolucci A, Pintus P, Roeters Van Lennep JE, Masana L, et al. Autosomal recessive hypercholesterolemia: long-term cardiovascular outcomes. J Am Coll Cardiol. 2018;71(3):279\u201388.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1999_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","volume":"152","author":"AA Kroon","year":"2000","unstructured":"Kroon AA, van\u2019t Hof MA, Demacker PNM, Stalenhoef AFH. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 2000;152(2):519\u201326.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1999_CR27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jacl.2016.04.013","volume":"10","author":"PB Duell","year":"2016","unstructured":"Duell PB, Santos RD, Kirwan B-A, Witztum JL, Tsimikas S, Kastelein JJP. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol. 2016;10(4):1011\u201321.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"1999_CR28","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacl.2016.06.007","volume":"10","author":"S B\u00e9liard","year":"2016","unstructured":"B\u00e9liard S, Millier A, Carreau V, Carri\u00e9 A, Moulin P, Fredenrich A, et al. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: analysis of 734 French patients. J Clin Lipidol. 2016;10(5):1129-1136.e3.","journal-title":"J Clin Lipidol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01999-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01999-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01999-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T12:12:43Z","timestamp":1631103163000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01999-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1999"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01999-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"21 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For the Italian cohort, informed consent was obtained from all patients before their inclusion into the study which was carried out in accordance with the ethical standards of local institutional committees for human experimentation in agreement with the Helsinki Declaration of 1964, as revised in 2018 (approval code #4928).The French cohort was declared to the ANSM (the French National Agency for Medicines safety) and received a declarant number [unique number identifying a particular research protocol, issued by the ANSM in France]: 2014-A01549-38. Two separate committees assessed the protocol of this study: French advisory committee on the processing of information for medical research (CCTIRS) and the National Commission for computer technology and freedom (CNIL) respectively in May and November 2015.Due to the retrospective nature of the present study, none of enrolled patients had received any procedures outside the standard clinical care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LD has received personal fees for public speaking, consultancy or grant support from Amryt Pharmaceuticals, Akcea Therapeutics, Pfizer, Amgen and Sanofi; AG has received honoraria from Amgen, Novartis, Unilever, Sanofi and Regeneron, Ackea Therapeutics, Mylan; ABC has served as a consultant for Amryt Pharmaceutical; and received lecturing fees from Amryt Pharmaceutical, MSD, Sanofi and AlfaSigma; MAV has served as a consultant for Amgen, Sanofi, Akcea, Novartin, Amgen; AP has received a lecturing fees from Sanofi and Amgen; TM has received a lecturing fees from Sanofi and Amgen; LP has received research grant support from Amgen, has served as a consultant for Akcea Therapeutics, and received lecturing fees from Sanofi, Rottapharm-MEDA; GF has received grant support from AMGEN; GI has received grant support and personal fees for public speaking from Amryt Pharmaceuticals, Akcea Therapeutics, Pfizer and Sanofi; SB has received honoraria for board, conferences, clinical trial or congress from Aegerion, Akcea, Elivie, Sanofi or Amgen; CP has received personal fees for public speaking from Amryt Pharmaceuticals; LC reports grants from Cerenis Therapeutics, grants and personal fees from MedImmune, grants from Alexion, grants from Sankyo, grants from Pfizer; MAR has received research grant support from Amryt Pharmaceutical, Amgen, IONIS, Akcea Therapeutics, Pfizer and Sanofi; has served as a consultant for Amgen, Aegerion, Akcea Therapeutics, Regeneron, Sanofi and Alfasigma and received lecturing fees from Amgen, Amryth Pharmaceutical, Pfizer, Sanofi and AlfaSigma; EB declares having received honoraria from AstraZeneca, Amgen, Genfit, MSD, Sanofi and Regeneron, Unilever, Danone, Aegerion, Chiesi, Rottapharm-MEDA, Lilly, Ionis-pharmaceuticals, Ackea Therapeutics. Other authors have declared no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"381"}}